blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3515446

EP3515446 - THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  17.11.2023
Database last updated on 24.07.2024
FormerGrant of patent is intended
Status updated on  05.07.2023
FormerExamination is in progress
Status updated on  10.06.2023
FormerGrant of patent is intended
Status updated on  06.02.2023
FormerExamination is in progress
Status updated on  18.12.2020
FormerRequest for examination was made
Status updated on  28.06.2019
FormerThe international publication has been made
Status updated on  24.03.2018
Formerunknown
Status updated on  13.10.2017
Most recent event   Tooltip19.07.2024Lapse of the patent in a contracting state
New state(s): EE		published on 21.08.2024 [2024/34]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2023/51]
Former [2019/31]For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Inventor(s)01 / CAPONIGRO, Giordano
c/o Novartis Institutes for
Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
02 / MEYER, Matthew John
c/o Novartis Institutes for
Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
03 / COOKE, Vesselina
c/o Novartis Institutes for
Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
04 / STUART, Darrin
c/o Novartis Institutes for
Biomedical Research Inc.
250 Massachusetts Avenue
Cambridge, MA 02139 / US
 [2019/31]
Representative(s)Evans, Sophie Elizabeth
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2023/51]
Former [2019/31]Rudge, Sewkian, et al
Novartis Pharma AG
Patent Department
4002 Basel / CH
Application number, filing date17778357.818.09.2017
[2019/31]
WO2017IB55641
Priority number, dateUS201662396504P19.09.2016         Original published format: US 201662396504 P
[2019/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018051306
Date:22.03.2018
Language:EN
[2018/12]
Type: A1 Application with search report 
No.:EP3515446
Date:31.07.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 22.03.2018 takes the place of the publication of the European patent application.
[2019/31]
Type: B1 Patent specification 
No.:EP3515446
Date:20.12.2023
Language:EN
[2023/51]
Search report(s)International search report - published on:EP22.03.2018
ClassificationIPC:A61K31/505, A61K31/5377, A61K45/06, A61P35/00
[2019/31]
CPC:
A61K31/5377 (EP,IL,KR,US); A61K31/4965 (IL,KR,US); A61K31/505 (EP,IL);
A61K45/06 (EP,IL); A61K9/0053 (IL,KR); A61P35/00 (EP,IL,KR,US);
A61K2300/00 (IL,KR) (-)
C-Set:
A61K31/505, A61K2300/00 (EP);
A61K31/5377, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/31]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:THERAPEUTISCHE KOMBINATIONEN MIT EINEM RAF-HEMMER UND EINEM ERK-HEMMER[2019/31]
English:THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR[2019/31]
French:COMBINAISONS THÉRAPEUTIQUES COMPRENANT UN INHIBITEUR DE RAF ET UN INHIBITEUR D'ERK[2019/31]
Entry into regional phase23.04.2019National basic fee paid 
23.04.2019Designation fee(s) paid 
23.04.2019Examination fee paid 
Examination procedure12.03.2019Amendment by applicant (claims and/or description)
23.04.2019Examination requested  [2019/31]
23.04.2019Date on which the examining division has become responsible
21.12.2020Despatch of a communication from the examining division (Time limit: M06)
21.07.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
23.09.2021Reply to a communication from the examining division
07.02.2023Communication of intention to grant the patent
09.06.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
06.07.2023Communication of intention to grant the patent
15.11.2023Fee for grant paid
15.11.2023Fee for publishing/printing paid
15.11.2023Receipt of the translation of the claim(s)
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
23.09.2021Request for further processing filed
23.09.2021Full payment received (date of receipt of payment)
Request granted
14.10.2021Decision despatched
Fees paidRenewal fee
13.09.2019Renewal fee patent year 03
14.09.2020Renewal fee patent year 04
12.09.2021Renewal fee patent year 05
26.08.2022Renewal fee patent year 06
24.08.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Licence(s)ID:01 00/exclusive
For:AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Licencee:Erasca, Inc.
3115 Merryfield Row, Suite 300
San Diego, CA 92121 / US
Date:14.12.2023
[2024/04]
Lapses during opposition  TooltipEE20.12.2023
FI20.12.2023
HR20.12.2023
LT20.12.2023
LV20.12.2023
NL20.12.2023
RS20.12.2023
SE20.12.2023
SM20.12.2023
BG20.03.2024
NO20.03.2024
GR21.03.2024
IS20.04.2024
[2024/34]
Former [2024/33]FI20.12.2023
HR20.12.2023
LT20.12.2023
LV20.12.2023
NL20.12.2023
RS20.12.2023
SE20.12.2023
SM20.12.2023
BG20.03.2024
NO20.03.2024
GR21.03.2024
IS20.04.2024
Former [2024/32]FI20.12.2023
HR20.12.2023
LT20.12.2023
LV20.12.2023
NL20.12.2023
RS20.12.2023
SE20.12.2023
BG20.03.2024
NO20.03.2024
GR21.03.2024
IS20.04.2024
Former [2024/26]FI20.12.2023
HR20.12.2023
LT20.12.2023
LV20.12.2023
NL20.12.2023
RS20.12.2023
SE20.12.2023
BG20.03.2024
NO20.03.2024
GR21.03.2024
Former [2024/24]FI20.12.2023
HR20.12.2023
LT20.12.2023
RS20.12.2023
SE20.12.2023
BG20.03.2024
NO20.03.2024
GR21.03.2024
Former [2024/21]FI20.12.2023
LT20.12.2023
BG20.03.2024
GR21.03.2024
Former [2024/20]GR21.03.2024
Cited inInternational search[AD]WO2014151616  (NOVARTIS AG [CH], et al);
 [AD]WO2015066188  (NOVARTIS AG [CH], et al);
by applicantWO2014151616
 WO2015066188
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.